Literature DB >> 31807428

Development of patient-derived xenograft models of prostate cancer for maintaining tumor heterogeneity.

Changhong Shi1,2, Xue Chen1,2, Dengxu Tan1.   

Abstract

Prostate cancer (Pca) is a heterogeneous disease with multiple morphological patterns. Thus, the establishment of a patient-derived xenograft (PDX) model that retains key features of the primary tumor is of great significance. This review demonstrates the characteristics and advantages of the Pca PDX model and summarizes the main factors affecting the establishment of the model. Because this model well recapitulates the diverse heterogeneity observed in the clinic, it was extensively utilized to discover new therapeutic targets, screen drugs, and explore metastatic mechanisms. In the future, clinical phenotype and different stages of the Pca patient might be faithfully reflected by PDX model, which provides tremendous potential for understanding Pca biology and achieving individualized treatment. 2019 Translational Andrology and Urology. All rights reserved.

Entities:  

Keywords:  Castration-resistant prostate cancer; heterogeneity; individualized treatment; patient-derived xenograft (PDX)

Year:  2019        PMID: 31807428      PMCID: PMC6842779          DOI: 10.21037/tau.2019.08.31

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


  66 in total

1.  Deletion of Y-chromosome specific genes in human prostate cancer.

Authors:  G Perinchery; M Sasaki; A Angan; V Kumar; P Carroll; R Dahiya
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

2.  Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.

Authors:  Gail P Risbridger; Renea A Taylor; David Clouston; Ania Sliwinski; Heather Thorne; Sally Hunter; Jason Li; Gillian Mitchell; Declan Murphy; Mark Frydenberg; David Pook; John Pedersen; Roxanne Toivanen; Hong Wang; Melissa Papargiris; Mitchell G Lawrence; Damien M Bolton
Journal:  Eur Urol       Date:  2014-08-22       Impact factor: 20.096

Review 3.  Engineering humanized mice for improved hematopoietic reconstitution.

Authors:  Adam C Drake; Qingfeng Chen; Jianzhu Chen
Journal:  Cell Mol Immunol       Date:  2012-03-19       Impact factor: 11.530

Review 4.  Breaking through a roadblock in prostate cancer research: an update on human model systems.

Authors:  R Toivanen; R A Taylor; D W Pook; S J Ellem; G P Risbridger
Journal:  J Steroid Biochem Mol Biol       Date:  2012-02-08       Impact factor: 4.292

5.  Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.

Authors:  Takahito Hara; Kazuyo Nakamura; Hideo Araki; Masami Kusaka; Masuo Yamaoka
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

Review 6.  Oncology meets immunology: the cancer-immunity cycle.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

7.  Organoid cultures derived from patients with advanced prostate cancer.

Authors:  Dong Gao; Ian Vela; Andrea Sboner; Phillip J Iaquinta; Wouter R Karthaus; Anuradha Gopalan; Catherine Dowling; Jackline N Wanjala; Eva A Undvall; Vivek K Arora; John Wongvipat; Myriam Kossai; Sinan Ramazanoglu; Luendreo P Barboza; Wei Di; Zhen Cao; Qi Fan Zhang; Inna Sirota; Leili Ran; Theresa Y MacDonald; Himisha Beltran; Juan-Miguel Mosquera; Karim A Touijer; Peter T Scardino; Vincent P Laudone; Kristen R Curtis; Dana E Rathkopf; Michael J Morris; Daniel C Danila; Susan F Slovin; Stephen B Solomon; James A Eastham; Ping Chi; Brett Carver; Mark A Rubin; Howard I Scher; Hans Clevers; Charles L Sawyers; Yu Chen
Journal:  Cell       Date:  2014-09-04       Impact factor: 41.582

8.  Testosterone inhibits the growth of prostate cancer xenografts in nude mice.

Authors:  Weitao Song; Vikram Soni; Samit Soni; Mohit Khera
Journal:  BMC Cancer       Date:  2017-09-07       Impact factor: 4.430

9.  Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.

Authors:  Steven Kregel; Kyle J Kiriluk; Alex M Rosen; Yi Cai; Edwin E Reyes; Kristen B Otto; Westin Tom; Gladell P Paner; Russell Z Szmulewitz; Donald J Vander Griend
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

View more
  6 in total

Review 1.  Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses.

Authors:  Xue Shui; Rong Xu; Caiqin Zhang; Han Meng; Jumei Zhao; Changhong Shi
Journal:  Lab Invest       Date:  2021-12-22       Impact factor: 5.662

2.  High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice.

Authors:  Riikka Huhtaniemi; Petra Sipilä; Arttu Junnila; Riikka Oksala; Matias Knuuttila; Arfa Mehmood; Eija Aho; Teemu D Laajala; Tero Aittokallio; Asta Laiho; Laura Elo; Claes Ohlsson; Malin Hagberg Thulin; Pekka Kallio; Sari Mäkelä; Mika V J Mustonen; Matti Poutanen
Journal:  iScience       Date:  2022-04-25

3.  Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [18F]DCFPyL PET Imaging.

Authors:  Jyoti Roy; Margaret E White; Falguni Basuli; Ana Christina L Opina; Karen Wong; Morgan Riba; Anita T Ton; Xiang Zhang; Keith H Jansson; Elijah Edmondson; Donna Butcher; Frank I Lin; Peter L Choyke; Kathleen Kelly; Elaine M Jagoda
Journal:  Mol Imaging Biol       Date:  2021-04-23       Impact factor: 3.488

Review 4.  Conditional reprogramming: Modeling urological cancer and translation to clinics.

Authors:  Wei Liu; Lingao Ju; Songtao Cheng; Gang Wang; Kaiyu Qian; Xuefeng Liu; Yu Xiao; Xinghuan Wang
Journal:  Clin Transl Med       Date:  2020-06-05

Review 5.  Exploring the Wnt Pathway as a Therapeutic Target for Prostate Cancer.

Authors:  Sarah Koushyar; Valerie S Meniel; Toby J Phesse; Helen B Pearson
Journal:  Biomolecules       Date:  2022-02-15

6.  IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation.

Authors:  Yipeng Xu; Gabriela Pachnikova; He Wang; Yaoyao Wu; Dorothea Przybilla; Reinhold Schäfer; Zihao Chen; Shaoxing Zhu; Ulrich Keilholz
Journal:  Bosn J Basic Med Sci       Date:  2022-07-29       Impact factor: 3.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.